Dendritic cells activated by IFN-γ/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment.

Horejs-Hoeck, J; Schwarz, H; Lamprecht, S; Maier, E; Hainzl, S; Schmittner, M; Posselt, G; Stoecklinger, A; Hawranek, T; Duschl, A; J IMMUNOL. 2012; 188(11): 5319-5326.

Canonical and noncanonical Hedgehog/GLI signaling in hematological malignancies.

Aberger, F; Kern, D; Greil, R; Hartmann, TN; Vitam Horm. 2012; 88:2-54

Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.

Preusser, M; Fülöp, G; Berghoff, AS; Heinzl, H; Steger, GG; Greil, R; Zielinski, CC; Bartsch, R; Oncologist. 2012; 17(7): e13-e17.

[Safety of immunosuppressants].

Psenak, O; Studnicka-Benke, A; Greil, R; Z Rheumatol. 2012; 71(5):420-429

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

Reinacher-Schick, A; Schulmann, K; Modest, DP; Bruns, N; Graeven, U; Jaworska, M; Greil, R; Porschen, R; Arnold, D; Schmiegel, W; Tannapfel, A BMC CANCER. 2012; 12: 349

Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers

Rick, FG; Buchholz, S; Schally, AV; Szalontay, L; Krishan, A; Datz, C; Stadlmayr, A; Aigner, E; Perez, R; Seitz, S; Block, NL; Hohla, F CELL CYCLE. 2012; 11(13): 2518-2525.

PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas

Laimer, D; Dolznig, H; Kollmann, K; Vesely, PW; Schlederer, M; Merkel, O; Schiefer, AI; Hassler, MR; Heider, S; Amenitsch, L; Thallinger, C; Staber, PB; Simonitsch-Klupp, I; Artaker, M; Lagger, S; Turner, SD; Pileri, S; Piccaluga, PP; Valent, P; Messana, K; Landra, I; Weichhart, T; Knapp, S; Shehata, M; Todaro, M; Sexl, V; Hofler, G; Piva, R; Medico, E; Ruggeri, BA; Cheng, MG; Eferl, R; Egger, G; Penninger, JM; Jaeger, U; Moriggl, R; Inghirami, G; Kenner, L NAT MED. 2012; 18(11): 1699-+.

Histiocytic sarcoma – targeted therapy: novel therapeutic options? A series of 4 cases.

Schlick, K; Aigelsreiter, A; Pichler, M; Reitter, S; Neumeister, P; Hoefler, G; Beham-Schmid, C; Linkesch, W Onkologie. 2012; 35(7-8):447-450

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.

Valent, P; Gastl, G; Geissler, K; Greil, R; Hantschel, O; Lang, A; Linkesch, W; Lion, T; Petzer, AL; Pittermann, E; Pleyer, L; Thaler, J; Wolf, D; Crit Rev Oncol Hematol. 2012; 82(3): 370-377.

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.

Thaler, J; Karthaus, M; Mineur, L; Greil, R; Letocha, H; Hofheinz, R; Fernebro, E; Gamelin, E; Baños, A; Köhne, CH; BMC Cancer. 2012; 12: 438